These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10537436)

  • 1. Pharmaceutical price regulation. A study on the impact of the rate-of-return regulation in the UK.
    Borrell JR
    Pharmacoeconomics; 1999 Mar; 15(3):291-303. PubMed ID: 10537436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An empirical analysis of the multimarket contact theory in pharmaceutical markets.
    Coronado J; Jiménez-Martín S; Marín PL
    Eur J Health Econ; 2014 Jul; 15(6):623-43. PubMed ID: 23818281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The UK pharmaceutical market. An overview.
    Towse A
    Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Price-cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals.
    Shajarizadeh A; Hollis A
    Health Econ; 2015 Aug; 24(8):966-77. PubMed ID: 24990225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Price regulation in the pharmaceutical industry: prescription or placebo?
    Abbott TA
    J Health Econ; 1995 Dec; 14(5):551-65. PubMed ID: 10156501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Creative compliance in pharmaceutical markets: the case of profit controls.
    Bradley J; Vandoros S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):31-8. PubMed ID: 22280194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitigating regulatory impact: the case of partial price controls on metformin in India.
    Bhaskarabhatla A; Chatterjee C; Anurag P; Pennings E
    Health Policy Plan; 2017 Mar; 32(2):194-204. PubMed ID: 28207048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
    Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
    Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of price-cap regulations on market entry by generic pharmaceutical firms.
    Zhang W; Sun H; Guh D; Anis AH
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):231-238. PubMed ID: 27936981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Drugs: An International Comparison of Postlicensing Price Inflation.
    Savage P; Mahmoud S; Patel Y; Kantarjian H
    J Oncol Pract; 2017 Jun; 13(6):e538-e542. PubMed ID: 28605615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms.
    Zhang W; Guh D; Sun H; Marra CA; Lynd LD; Anis AH
    Med Care; 2016 Sep; 54(9):884-90. PubMed ID: 27213540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical price controls and minimum efficacy regulation: evidence from the United States and Italy.
    Atella V; Bhattacharya J; Carbonari L
    Health Serv Res; 2012 Feb; 47(1 Pt 1):293-308. PubMed ID: 22091623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
    Bardey D; Bommier A; Jullien B
    J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How competition lowers the costs of medicines.
    Reekie WD
    Pharmacoeconomics; 1998; 14 Suppl 1():107-13. PubMed ID: 10186472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallel imports, price controls, and innovation.
    Reisinger M; Saurí L; Zenger H
    J Health Econ; 2019 Jul; 66():163-179. PubMed ID: 31202122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.